PetVivo Holdings Inc.
1.4500-0.04 (-2.68%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQX · PETV · USD
Key Stats
Market Cap
45.78MP/E (TTM)
-Basic EPS (TTM)
-0.39Dividend Yield
0%Recent Filings
8-K
Debt-to-equity conversion completed
PetVivo Holdings converted $2,018,155 in outstanding promissory notes from four shareholders into 3,669,806 restricted common shares at prices ranging from $0.50 to $0.75 per share, effective September 30, 2025. This fully settles the debt, including $1.85 million principal and $168,155 accrued interest, eliminating related obligations. The move strengthens the balance sheet by swapping liabilities for equity. No further debt remains with these lenders.
10-Q
Q1 FY2026 results
PetVivo Holdings boosted revenues to $297,500 in Q1 FY2026 ended June 30, 2025, up 140% year-over-year from $123,751, thanks to Precise PRP sales under its new VetStem license alongside Spryng product gains; gross profit climbed to $186,726 from $110,757, yet operating loss narrowed to $1.8M from $2.0M on tighter G&A and R&D spending. Net loss widened to $2.3M or $0.09 per share from $2.0M or $0.11, driven by a $320K unrealized derivative hit and $149K asset disposal loss, while Series B dividends added $29K drag—anti-dilution kept EPS steady despite 30% more shares. Cash swelled to $3.3M after $4.4M Series B funding, covering $1.6M operating burn; non-GAAP metrics not disclosed in the 10-Q. Signed exclusive VetStem deal in February 2025 for $2M fee (cash/stock/future payments), amortizing over 60 months with 3-4.5% royalties starting month seven. Lease terminated June 2025 for $315K fees. Debt stands at $1.5M convertible notes (10-12% rates, maturities to December 2025). Competition from NSAIDs and injectables pressures adoption.
10-K
FY2025 results
PetVivo Holdings posted FY2025 revenue of $1.13 million, up 17% y/y from $969K in FY2024, driven by Spryng® sales to distributors ($956K) and clinics ($176K), with Precise PRP adding momentum in Q4 via the VetStem license. While annual operating expenses fell 21% to $9.05 million on lower G&A and marketing, Q4 showed sequential revenue acceleration from Q3, though R&D rose 13% y/y to $1.58 million for clinical studies. Net loss narrowed to $8.40 million ($0.41/share) from $10.96 million ($0.78/share), aided by 47% more diluted shares (20.5 million). Liquidity stood at $228K cash with $2.09 million in notes, bolstered by $5 million Series B funding; no dividends or buybacks, but capex supported manufacturing expansion. No annual guidance disclosed in the 10-K. Yet distribution shifts risk quarterly sales volatility.
8-K
PetVivo Closes $5M Funding
PetVivo Holdings completed its $5 million Series B Convertible Preferred Stock offering on June 24, 2025, with an investor fully exercising the remaining $1 million purchase option for 1 million shares at $1.00 each, convertible one-for-one into common stock. This caps prior $4 million raised, providing funds for commercializing Spryng and PrecisePRP products, clinical trials, and working capital. Proceeds bolster liquidity amid high-risk biotech operations. Yet dilution looms large.
8-K
PetVivo secures $3M funding
PetVivo Holdings secured $3 million on June 20, 2025, via partial exercise of a purchase option in its $5 million Series B Convertible Preferred Stock offering, bringing total funds received to $4 million with $1 million more anticipated by June 26. The proceeds will fuel commercialization of Spryng with OsteoCushion Technology and PrecisePRP, clinical trials, and working capital. This infusion bolsters liquidity for product advancement. Yet dilution looms for common shareholders.
BVS
Bioventus Inc.
6.77-0.17
IVP
Inspire Veterinary Partners, In
0.84-0.03
LIVN
LivaNova PLC
53.34-0.52
PETS
PetMed Express, Inc.
2.59+0.02
PTPI
Petros Pharmaceuticals, Inc.
0.02-0.00
RBOT
Vicarious Surgical Inc.
5.45-0.30
RDGL
Vivos Inc.
0.08-0.00
VVOS
Vivos Therapeutics, Inc.
2.67+0.07
ZIVO
Zivo Bioscience, Inc.
16.99-0.01
ZOMDF
Zomedica Corp.
0.07+0.00